Impact Factor
Research Paper DCTN2 inhibited cellular senescence through targeting TRIM21 mediated MST2 ubiquitination and activation in hepatocellular carcinoma Full text PDF
Research Paper A nanoengineered MSC therapeutic for synergistic therapy of lupus nephritis via cfDNA clearance and targeted immunomodulation Full text PDF
Review Atherosclerosis nanotheranostics: a perspective from macrophages Full text PDF
Research Paper Oral inulin prebiotic encapsulating Cortex Fraxini extracellular vesicles alleviates colitis and associated renal stress via reinforcing intestinal barriers and remodeling microbiota Full text PDF
Research Paper Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer Full text PDF
Research Paper mRNA-dendritic cell antigen vaccine potentiates CD38 CAR-T Cell therapy for relapsed/refractory acute myeloid leukemia Full text PDF
Issue 13; 2026
Founding Editor-in-Chief:
Prof. Xiaoyuan (Shawn) Chen, PhD
Profile
Theranostics publishes innovative research articles reflecting the fields of in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensors, system biology and translational medicine, personalized medicine and a broad spectrum of biomedical research that can be applied to future theranostic applications.
- Theranostics is indexed by Science Citation Index (SCI) and MEDLINE. (Full index information)
- Full texts of articles in PubMed Central and Europe PMC. Abstracts in PubMed.
- (For NIH-funded researchers) Save time by submitting your paper to us - this journal is in full compliance with NIH Public Access Requirement.
Special Issue - Advanced Cell and Gene Therapy Strategies for Precision Treatment of Autoimmune Diseases. Theme issue editors: Weisheng Guo (Guangzhou Medical University), Xiaoyuan Chen (Shandong Cancer Hospital and Institute).
Background: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising strategy for management of relapsed/refractory acute myeloid leukemia (R/R AML). Safety and preliminary activity of CD38-targeted CAR-T cells in R/R AML were demonstrated in our prior study; however, relapse with CD38-positive blasts persisted, which was partly associated with insufficient effector function and persistence of CAR-T cells. Given that CAR-T cell hypofunction ...